Open figure viewer
Significance
Klugge is likely aiming to be optimistic. An effective COVID-19 vaccine is considered to be the only economically and humanely acceptable exit strategy for this pandemic. However, never before has a vaccine been developed, manufactured and distributed in the timescale now required.
Impacts
High-income countries will initially monopolise access to a vaccine.
The country in which the vaccine is developed will be the very first to use it.
Low- and middle-income countries covered by GAVI will gain some access to a vaccine, but it will not be comprehensive.
Middle-income countries outside GAVI will likely be the last to get access.
Keywords:
International,
INT,
United Kingdom,
EU,
Europe,
United States,
politics,
health,
Pharm, biotech & life sciences
© Oxford Analytica 2020. All rights reserved. This content contains general information about geopolitical, macroeconomic and social developments or (where stated) other matters. It does not contain advice or recommendations that may be relied on. Where links to external websites are provided, this does not indicate that Oxford Analytica or Emerald agree with, endorse or have checked for accuracy the contents of said sites.
2020
You do not currently have access to this content.
